FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:36-46 January 3, 2008 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer.

Methods In a two-by-two design, we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil (EOF) or capecitabine (EOX). The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin.

Results For the capecitabine–fluorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); for the oxaliplatin–cisplatin comparison, the hazard ratio for the oxaliplatin group was 0.92 (95% CI, 0.80 to 1.10). The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 1.23. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.9 months, 9.9 months, 9.3 months, and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4%, and 46.8%, respectively. In the secondary analysis, overall survival was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; P=0.02). Progression-free survival and response rates did not differ significantly among the regimens. Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy.

Conclusions Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883 [controlled-trials.com] .)

Source Information

From Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London (D.C., N.S., S.R., J.O., A.R.N.); Southampton University Hospital National Health Service Trust, Southampton, and Salisbury Hospital National Health Service Foundation Trust, Salisbury (T.I.); Aberdeen Royal Infirmary, Aberdeen (M.N.); Northern Centre for Cancer Treatment, Newcastle upon Tyne (F.C.); St. Luke's Cancer Centre, Guildford (G.M.); and Plymouth Oncology Centre, Plymouth (F.D.) — all in the United Kingdom.

Full Text of this Article

Related Letters:

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Bölke E., Peiper M., Budach W., Cunningham D., Starling N.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1965, May 1, 2008. Correspondence

This article has been cited by other articles:

• Fornaro, L., Vasile, E., Masi, G., Loupakis, F., Caponi, S., Ginocchi, L., Falcone, A. (2009). Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. Ann Oncol 0: mdp469v1-mdp469 [Full Text]  
• Koizumi, W., Takiuchi, H., Yamada, Y., Boku, N., Fuse, N., Muro, K., Komatsu, Y., Tsuburaya, A. (2009). Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 0: mdp464v1-mdp464 [Abstract] [Full Text]  
• Kang, Y.-K. (2009). Reply to 'Are we representing the true population in oncology trials?'. Ann Oncol 0: mdp462v1-mdp462 [Full Text]  
• Lord, S. R., Hall, P. S., Seymour, M. T. (2009). Are we representing the true population in oncology trials?. Ann Oncol 0: mdp461v1-mdp461 [Full Text]  
• Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., Cunningham, D. (2009). Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20: 1529-1534 [Abstract] [Full Text]  
• Jansen, E. P. M., Boot, H., Dubbelman, R., Verheij, M., Cats, A. (2009). Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol 0: mdp345v1-mdp345 [Abstract] [Full Text]  
• Starling, N., Rao, S., Cunningham, D., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., Norman, A. R. (2009). Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. JCO 27: 3786-3793 [Abstract] [Full Text]  
• FUJITANI, K., TSUJINAKA, T., YAMASAKI, H., HIRAO, M., YOSHIDA, K., KUROKAWA, Y. (2009). Feasibility Study of S-1 plus Weekly Docetaxel Combined with Concurrent Radiotherapy in Advanced Gastric Cancer Refractory to First-line Chemotherapy. Anticancer Res 29: 3385-3391 [Abstract] [Full Text]  
• Moehler, M., Kanzler, S., Geissler, M., Raedle, J., Ebert, M. P., Daum, S., Flieger, D., Seufferlein, T., Galle, P. R., Hoehler, T., for the Arbeitsgemeinschaft Internistische Onkolog, (2009). A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 0: mdp269v1-mdp269 [Abstract] [Full Text]  
• Chau, I., Ashley, S., Cunningham, D. (2009). Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. JCO 27: e3-e4 [Full Text]  
• Burtness, B., Gibson, M., Egleston, B., Mehra, R., Thomas, L., Sipples, R., Quintanilla, M., Lacy, J., Watkins, S., Murren, J. R., Forastiere, A. A. (2009). Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 20: 1242-1248 [Abstract] [Full Text]  
• MATSUDA, G., KUNISAKI, C., MAKINO, H., FUKAHORI, M., KIMURA, J., SATO, T., OSHIMA, T., NAGANO, Y., FUII, S., TAKAGAWA, R., KOSAKA, T., ONO, H. A., AKIYAMA, H., ICHIKAWA, Y. (2009). Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer. Anticancer Res 29: 2863-2867 [Abstract] [Full Text]  
• Kwak, E. L., Hong, T. S., Berger, D. L., Forcione, D. G., Uppot, R. N., Lauwers, G. Y. (2009). Case 19-2009 -- A 63-Year-Old Woman with Carcinoma of the Gastroesophageal Junction. NEJM 360: 2656-2664 [Full Text]  
• Chau, I., Norman, A. R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M., Hickish, T. (2009). The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20: 885-891 [Abstract] [Full Text]  
• Jackson, C., Cunningham, D., Oliveira, J., On behalf of the ESMO Guidelines Working Group, (2009). Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv34-iv36 [Full Text]  
• Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., Philco-Salas, M., Suarez, T., Santamaria, J., Forster, G., McCloud, P. I. (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20: 666-673 [Abstract] [Full Text]  
• Wong, R., Cunningham, D. (2009). Optimising treatment regimens for the management of advanced gastric cancer. Ann Oncol 20: 605-608 [Full Text]  
• Goekkurt, E., Al-Batran, S.-E., Mogck, U., Pauligk, C., Hartmann, J. T., Kramer, M., Jaeger, E., Ehninger, G., Stoehlmacher, J. (2009). Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 20: 481-485 [Abstract] [Full Text]  
• Samol, J., Waterston, A. (2009). Oxaliplatin-induced coronary artery spasm: first report of an important side-effect. BMJ Case Reports 2009: bcr0620080334-bcr0620080334 [Abstract] [Full Text]  
• Ricart, A. D., Berlin, J. D., Papadopoulos, K. P., Syed, S., Drolet, D. W., Quaratino-Baker, C., Horan, J., Chick, J., Vermeulen, W., Tolcher, A. W., Rowinsky, E. K., Rothenberg, M. L. (2008). Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors. Clin. Cancer Res. 14: 7947-7955 [Abstract] [Full Text]  
• Al-Batran, S.-E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., Stoehlmacher, J., Clemens, M. R., Mahlberg, R., Fritz, M., Seipelt, G., Sievert, M., Pauligk, C., Atmaca, A., Jager, E. (2008). Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19: 1882-1887 [Abstract] [Full Text]  
• Tan, B. R., Brenner, W. S., Picus, J., Marsh, S., Gao, F., Fournier, C., Fracasso, P. M., James, J., Yen-Revollo, J. L., Mcleod, H. L. (2008). Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol 19: 1742-1748 [Abstract] [Full Text]  
• Matsubara, J., Shimada, Y., Takashima, A., Takahari, D., Hirashima, Y., Okita, N. T., Nakajima, T. E., Kato, K., Hamaguchi, T., Yamada, Y., Shirao, K. (2008). A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer. Jpn J Clin Oncol 38: 540-546 [Abstract] [Full Text]  
• Pozzo, C., Barone, C. (2008). Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents?. The Oncologist 13: 794-806 [Abstract] [Full Text]  
• Khushalani, N. I. (2008). Cancer of the Esophagus and Stomach. Mayo Clin Proc. 83: 712-722 [Abstract] [Full Text]  
• Bolke, E., Peiper, M., Budach, W., Cunningham, D., Starling, N. (2008). Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. NEJM 358: 1965-1965 [Full Text]  
• (2008). Capecitabine and Oxaliplatin Are Effective in Advanced Gastric Cancer. JWatch Oncology and Hematology 2008: 6-6 [Full Text]